Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer.

Marina Hodolic, Valentina Ambrosini, Stefano Fanti

Nuclear medicine communications 2020 May

filter terms:

Pancreatic cancer is the fourth leading cause of cancer-related death in both men and women. Neurotensin receptors are overexpressed in different malignancies, above all pancreatic cancer. On the other hand, neurotensin receptor expression in inflammation is quite low. This fact can probably solve the most important problem of F-FDG PET imaging - distinguishing malignant and inflammatory processes. The first therapeutic injection of radiolabelled neurotensin in human with pancreatic cancer has been successfully performed. Animal experiments are also very close to the first in human injection of radiolabelled neurotensin for diagnostic purposes. The purpose of this article is to provide an overview of radiolabelled neurotensin analogues that can be used in imaging and therapy in patients with pancreatic ductal adenocarcinoma.

Citation

Marina Hodolic, Valentina Ambrosini, Stefano Fanti. Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer. Nuclear medicine communications. 2020 May;41(5):411-415